Evidence map›Paper›PMID 25337042›Full record

ReviewReviews in urology2014

The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.

Vladimir Mouraviev, Neil Mariados, David Albala, Raoul S Concepcion, Neal D Shore, Robert B Sims, Mark Emberton, Christopher M Pieczonka

Open access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in Reviews in urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Vladimir MouravievAssociated Medical Professionals of New York, Syracuse, NY.
Neil MariadosAssociated Medical Professionals of New York, Syracuse, NY.
David AlbalaUrology Associates, Nashville, TN.
Raoul S ConcepcionUrology Associates, Nashville, TN.
Neal D ShoreCarolina Urologic Research Center, 21st Century Oncology, Myrtle Beach, SC.
Robert B SimsDendreon Corporation, Seattle, WA.
Mark EmbertonUniversity College of London, London, UK.
Christopher M PieczonkaAssociated Medical Professionals of New York, Syracuse, NY.
Urology Associates · USCarolina Urologic Research Center · USDendreon (United States) · USUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy encourages the recipient's own immune response to destroy cancer cells, and current evidence suggests that immunotherapies may be most beneficial in early metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T is the first therapeutic cancer vaccine to be approved by both the US Food and Drug Administration and European Medicines Agency for the treatment of asymptomatic or minimally symptomatic mCRPC. Combining immunotherapy with other treatments may have potent anticancer effects; cytoreductive therapies can release tumor antigens and promote a proinflammatory environment that could augment immunotherapies. However, some cytoreductive agents or coadministered drugs may be immunosuppressive. Understanding these interactions between different mCRPC treatment modalities may offer further potential to improve patient outcomes.

Indexed as

Combination therapyProstate cancerSipuleucel-T

Identifiers

PMID25337042
PMCPMC4191632
OpenAlexW2345317256

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.